Publications

 


  • 378. PSA 1960 – 2010: een bijzondere periode ( in Dutch)

    Blijenberg BG, 2009

    Journal: Ned Tijdschr Klin Chem Labgeneesk
    Reference: 34: 168-173

    paper

  • 377. de Koning HJ, Hugosson J, Auvinen A. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

    Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM,, 2009

    Journal: Eur Urol
    Reference: Oct;56(4):584-91

    paper

  • 376. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial

    Murtola TJ, Tammela TL, Määttänen L, Ala-Opas M, Stenman UH, Auvinen A., 2009

    Journal: Br J Cancer
    Reference: 14-08-04

    paper

  • 375. Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands.

    Auvinen A, Raitanen J, Moss S, de Koning HJ, Hugosson J, Tammela T, Roobol M, Lilja H, Hakama M., 2009

    Journal: Cancer Epidemiol Biomarkers Prev
    Reference: Jul;18(7):2000-5

  • 374. Anxiety and distress during active surveillance for early prostate cancer.

    van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T, Schröder FH, Bangma CH, Steyerberg EW., 2009

    Journal: Cancer
    Reference: 1;115(17):3868-78

    paper

  • 373. Disease insight and treatment perception of men on active surveillance for early prostate cancer.

    van den Bergh RC, van Vugt HA, Korfage IJ, Steyerberg EW, Roobol MJ, Schröder FH, Essink-Bot ML., 2010

    Journal: BJUI
    Reference: Feb;105(3):322-8

    paper

  • 372. Predictive models in diagnosing indolent cancer.

    Bangma CH, Roobol MJ, Steyerberg EW., 2009

    Journal: Cancer
    Reference: Jul 1;115(13 Suppl):3100-6

  • 371. Words of wisdom. Re: Mortality results from a randomized prostate-cancer screening Trial.

    Roobol MJ, 2009

    Journal: Eur Urol
    Reference: Jun;55(6):1481-2

    paper

  • 370. Screening for prostate cancer appears to work, but at what cost?

    Parker C, Emberton M., 2009

    Journal: BJUI
    Reference: Aug;104(3):290-2

    paper

  • 369. Prostate cancer: To screen or not to screen?

    Studer UE, Collette L, 2009

    Journal: Nat Rev Urol
    Reference: Jun;6(6):299-301

    paper

  • 368. Screening:should more biopsies be taken in larger prostates?

    van Leeuwen P, van den Bergh R, Wolters T, Schröder F, Roobol MJ., 2009

    Journal: BJUI
    Reference: May 18

    paper

  • 367. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.

    Schröder FH, Roobol MJ, 2009

    Journal: Curr Opin Urol
    Reference: May;19(3):227-31

    paper

  • 366. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)

    Wolters T, Roobol MJ, Bangma CH, Schröder FH., 2009

    Journal: Eur Urol
    Reference: Feb;55(2):385-92

    paper

  • 365. Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault

    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A., 2009

    Journal: Prog Urol
    Reference: Jul;19(7):487-98

    paper

  • 364. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context

    Draisma G, Etzioni R ,Tsodikov A ,Mariotto A ,Wever E ,Gulati R ,Feuer E , de Koning HJ, 2009

    Journal: JNCI
    Reference: 101: 374 – 383

    paper

  • 363. Transcript of round table discussion on ERSPC and PLCO trial published in NEJM , March 26 2009

    Lee T, Kandoff P, McNaughton-Collins M., 2009

    Journal: NEJM
    Reference: March 26

    paper

  • 362. Screening for prostate cancer–the controversy that refuses to die.

    Barry MJ, 2009

    Journal: NEJM
    Reference: Mar 26;360(13):1351-4

    paper

  • 361. Mortality results from a randomized prostate-cancer screening trial.

    Andriole GL, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Crawford ED, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohaga, 2009

    Journal: NEJM
    Reference: Mar 26;360(13):1310-9

    paper

  • 360. Screening and prostate-cancer mortality in a randomized European study.

    Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auv, 2009

    Journal: NEJM
    Reference: Mar 26;360(13):1320-8

    paper

  • 359. Non-prostatic pathology on prostate needle-biopsy – colorectal carcinoid: a case report.

    van den Bergh RCN, Wolters T, Spaander MC, Schröder FH, van Leenders GJ., 2009

    Journal: Cases J
    Reference: Jan 21;2(1):75.

    paper

  • 358. Erectile dysfunction and mental health in a general population of older men.

    Korfage IJ, Pluijm S, Roobol M, Dohle GR, Schröder FH, Essink-Bot ML., 2009

    Journal: J Sex Medicine
    Reference: Feb;6(2):505-12

    paper

  • 357. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.

    van den Bergh RCN, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH., 2009

    Journal: BJUI
    Reference: Jun;103(11):1472-7

    paper

  • 356. Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.

    Schröder FH, Roobol MJ., 2009

    Journal: BJUI
    Reference: Jan;103(2):143-4

    paper

  • 355. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.

    Schröder FH, Roobol MJ, Andriole GL, Fleshner N., 2009

    Journal: J Urol
    Reference: Jan;181(1):69-74

    paper

  • 354. Biological aggressiveness of prostate cancer in the Finnish screening trial.

    Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Luukkaala T, Määttänen L, Ruutu M, Ala-Opas M, Mildh M, Martikainen P., 2009

    Journal: Int J Cancer
    Reference: 1;124(3):547-52.

  • 352. Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection.

    Jansen FH, Roobol M, Bangma CH, van Schaik RH., 2008

    Journal: Clin Chem
    Reference: 54(12):1999-2006

    paper

  • 351. Predictive Modeling in Prostate Cancer: A Conference Summary.

    Valdagni R, Scardino PT, Denis L, Kattan MW., 2009

    Journal: Eur Urol
    Reference: Feb;55(2):300-2

    paper

  • 350. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

    Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H., 2008

    Journal: BMC Med
    Reference: Jul 8;6:19

    paper

  • 348. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.

    van den Bergh RC, Roobol MJ, Wolters T, van Leeuwen PJ, Schröder FH., 2008

    Journal: BJU Int
    Reference: 102(9):1068-73

    paper

  • 347. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate- specific antigen relapse after radical prostatectomy.

    Khatami A, Hugosson J, Wang W, Damber JE., 2008

    Journal: Scand J Urol Nephrol.
    Reference: Oct 23:1-7

  • 346. A graphical device to represent the outcomes of a logistic regression analysis.

    Kranse R, Roobol MJ, Schröder FH., 2008

    Journal: Prostate
    Reference: 68(15):1674-80.

    paper

  • 345. Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review.

    Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R., 2009

    Journal: Eur Urol
    Reference: Apr;55(4):864-73.

    paper

  • 344. Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer.

    van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH., 2008

    Journal: Eur Urol
    Reference: xx-xx

    paper

  • 343. Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly.

    van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH., 2008

    Journal: Eur Urol
    Reference: xx-xx

    paper

  • 342. Screening for prostate cancer (PC)–an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

    Schröder FH., 2008

    Journal: Urol Oncol
    Reference: 26(5):533-41

    paper

  • 341. PSA use and incidence of prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects with PSA elevation?

    Ciatto S, Houssami N, Martinelli F, Giusti F, Zappa M., 2008

    Journal: Tumori
    Reference: 94(4):518-22

  • 340. PSA doubling time as a predictor of the outcome of random prostate biopsies prompted by isolated PSA elevation in subjects referred to an outpatient biopsy facility in a routine clinical scenario.

    Ciatto S, Rubeca T, Martinelli F, Pontenani G, Lombardi C, Di Lollo S., 2008

    Journal: Int J Biomarkers
    Reference: 23(3):187-91

  • 339. “Does “”normal”” aging imply urinary, bowel, and erectile dysfunction? A general population survey.”

    Korfage IJ, Roobol MJ, de Koning HJ, Kirkels WJ, Schröder FH, Essink-Bot ML., 2008

    Journal: Urology
    Reference: Jul;72(1):3-9

    paper

  • 338. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.

    Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schröder FH, Klein EA., 2008

    Journal: J urol
    Reference: 180(1):150-4

    paper

  • 337. Prostate-Specific Antigen Kinetics in Clinical Decision-Making During Active Surveillance for Early Prostate Cancer—A Review

    van den Bergh RCN, Roemeling S, Roobol MJ, Wolters T, Schröder FH, Bangma CH, 2008

    Journal: Eur Urol
    Reference: 54(3):505-516

    paper

  • 336. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.

    Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH., 2008

    Journal: Prostate
    Reference: Jun 15;68(9):985-93

    paper

  • 335. Editorial comment on:The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam: Digital Rectal Examination Remains an Important Screening Tool for Prostate Cancer

    Yossepowitch O, 2008

    Journal: Eur Urol
    Reference: 54(3):483-484

    paper

  • 334. The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.

    Gosselaar C, Roobol MJ, Roemeling S, Schröder FH., 2008

    Journal: Eur Urol
    Reference: 54(3):581-588

    paper

  • 333. Editorial comment on: Digital Rectal Examination and the Diagnosis of Prostate Cancer—a Study Based on 8 Years and Three Screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC),

    Ciatto S, 2009

    Journal: Eur Urol
    Reference: 55.(1): 139-147,

    paper

  • 332. Digital Rectal Examination and the Diagnosis of Prostate Cancer-a Study Based on 8 Years and Three Screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.

    Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schröder FH., 2009

    Journal: Eur Urol
    Reference: 55.91):139-147

    paper

  • 331. Reply from Authors re: Martha K. Terris. Editorial Comment on: Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer In Screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

    Wolters T, Schröder FH., 2009

    Journal: Eur Urol
    Reference: 2009 Feb;55(2):393

    paper

  • 330. Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

    Wolters T, Roobol MJ, Bangma CH, Schröder FH., 2009

    Journal: Eur Urol
    Reference: 2009 Feb;55(2):385-92

    paper

  • 329. Algorithms, nomograms and the detection of indolent prostate cancer

    Roobol MJ, 2008

    Journal: World J Urol
    Reference: 26(5):423-429

    paper

  • 328. Words of wisdom:(II) Re: Prostate Specific Antigen Velocity in Men with Total Prostate Specific Antigen Less than 4 ng/ml

    Roobol MJ, 2008

    Journal: Eur Urol
    Reference: 53: 854-855

    paper

  • 327. Words of wisdom: (I) Re: Prostate Specific Antigen Velocity in Men with Total Prostate Specific Antigen Less than 4 ng/ml

    Roobol MJ, 2008

    Journal: Eur Urol
    Reference: 53: 852–854

    paper

← PreviousNext →